Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non-cash Items (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Non-cash Items for 4 consecutive years, with $8.5 million as the latest value for Q4 2025.

  • Quarterly Non-cash Items changed N/A to $8.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.5 million through Dec 2025, changed N/A year-over-year, with the annual reading at $8.5 million for FY2025, 3370.33% up from the prior year.
  • Non-cash Items hit $8.5 million in Q4 2025 for Insight Molecular Diagnostics, up from $306000.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $19.1 million in Q4 2021 to a low of $51.0 in Q2 2024.
  • Historically, Non-cash Items has averaged $3.6 million across 3 years, with a median of $211000.0 in 2024.
  • Biggest YoY gain for Non-cash Items was 223429.41% in 2025; the steepest drop was 28.5% in 2025.
  • Year by year, Non-cash Items stood at $19.1 million in 2021, then tumbled by 98.8% to $229000.0 in 2024, then soared by 3627.95% to $8.5 million in 2025.
  • Business Quant data shows Non-cash Items for IMDX at $8.5 million in Q4 2025, $306000.0 in Q3 2025, and $114000.0 in Q2 2025.